Qianhong Biopharmaceutical

Changzhou Qianhong Biopharmaceutical is a leading Chinese pharmaceutical company specializing in the research, development, and large-scale production of biochemical drugs, particularly enzymes and polysaccharides. The company is a globally recognized manufacturer of Heparin Sodium and Enoxaparin Sodium for anticoagulation, as well as Pancreatic Kallidinogenase used to treat microcirculation disorders and diabetic complications. Its commercial portfolio also includes Asparaginase for the treatment of acute leukemia and Elastase for hyperlipidemia. Listed on the Shenzhen Stock Exchange, Qianhong is aggressively transitioning toward innovative drug discovery, with a pipeline of small molecule inhibitors targeting JAK, BTK, and CDK4/6 pathways. The company maintains robust manufacturing capabilities with international GMP certifications, serving both the domestic Chinese market and over 20 countries worldwide.